We were delighted to talk to Diego Maselli (University of Texas Health Science Center at San Antonio, TX, US) around the effects of Body Mass Index (BMI) on response to the triple therapy of fluticasone furoate, umeclidinium, and vilanterol in patients with inadequately controlled asthma (Clinical Trial Identifier: NCT02924688).
The abstract ‘CAPTAIN: Effects of Body Mass Index (BMI) on Response to Triple Therapy in Patients With Inadequately Controlled Asthma on Inhaled Corticosteroids/Long-acting b2-agonists (ICS/ LABA).’ (ABSTRACT NUMBER: 176) was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021.
Questions
- What has the CAPTAIN trial taught us about the clinical utility of the single inhaler triple therapy of fluticasone furoate, umeclidinium, and vilanterol in the treatment of patients with uncontrolled asthma? (0:23)
- What were the results of your analysis of the CAPTAIN study data in subgroups defined by BMI? (1:18)
- What are the implications of these findings for asthma therapy? (3:06)
- What are the remaining unanswered questions regarding the use of this triple therapy? (3:50)
Disclosures: Diego Maselli discloses consulting fees from GSK, AstraZeneca, Sanofi/Regeneron and Amgen.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAAAI 2021 (Virtual).
